Federated Hermes, Inc. Aravive, Inc. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.93 - $1.9 $410 - $837	-441 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$1.85 - $2.75 $62,772 - $93,310	-33,931 Reduced 98.72%	441 $1,000
Q3 2021 Nov 15, 2021	SELL	$3.67 - $5.8 $869 - $1,374	-237 Reduced 0.68%	34,372 $128,000
Q2 2021 Aug 16, 2021	BUY	$4.65 - $6.42 $160,931 - $222,189	34,609 New	34,609 $207,000
Q3 2020 Nov 12, 2020	SELL	$4.7 - $12.06 $408 - $1,049	-87 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$5.18 - $14.81 $450 - $1,288	87 New	87 $1,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.